Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Denisa Miklankova"'
Autor:
Tereza Kacerova, Ludmila Kazdova, Petr Kacer, Irena Markova, Jelena Skibova, Jan Kučera, Denisa Miklankova, Martina Hüttl, Hana Malinska, Radislav Sedlacek
Publikováno v:
Journal of Diabetes Research, Vol 2019 (2019)
Journal of Diabetes Research
Journal of Diabetes Research
Introduction. The development of metabolic syndrome-associated renal dysfunction is exacerbated by a number of factors including dyslipidemia, ectopic deposition of lipids and their toxic metabolites, impairment of lipid metabolism, and insulin resis
Autor:
Hana Malinska, Iveta Zapletalova, Martin Haluzik, Denisa Miklankova, Irena Markova, Martin Poruba, Martina Hüttl, Ivana Vaněčková
Publikováno v:
International Journal of Molecular Sciences
Volume 22
Issue 21
International Journal of Molecular Sciences, Vol 22, Iss 11513, p 11513 (2021)
Volume 22
Issue 21
International Journal of Molecular Sciences, Vol 22, Iss 11513, p 11513 (2021)
Recent studies suggest that treatment with SGLT-2 inhibitors can reduce hepatic lipid storage and ameliorate non-alcoholic fatty liver disease (NAFLD) development beyond their glycemic benefits. However, the exact mechanism involved is still unclear.
Autor:
Jan Neckář, Michaela Kadlecová, Martina Hüttl, S Hojná, Denisa Miklankova, Frantisek Papousek, Michal Behuliak, Josef Zicha, Hana Rauchová, Hana Malinska, Petr Kujal, Zdeňka Vaňourková, Ivana Vaněčková, Irena Markova
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 144, Iss, Pp 112246-(2021)
The new antidiabetic drugs, gliflozins, inhibit sodium-glucose transporter-2 in renal proximal tubules promoting glucose and sodium excretion. This leads not only to a significant improvement of glucose control but also to the reduction of blood pres
Autor:
Iveta Zapletalova, Martina Hüttl, Denisa Miklankova, Hana Malinska, Martin Poruba, Irena Markova
Publikováno v:
International Journal of Molecular Sciences
Volume 22
Issue 14
International Journal of Molecular Sciences, Vol 22, Iss 7680, p 7680 (2021)
Volume 22
Issue 14
International Journal of Molecular Sciences, Vol 22, Iss 7680, p 7680 (2021)
Metformin can reduce cardiovascular risk independent of glycemic control. The mechanisms behind its non-glycemic benefits, which include decreased energy intake, lower blood pressure and improved lipid and fatty acid metabolism, are not fully underst